October 11th, 2013
•Three assays, including the cytopathic effect (CPE)-based assay, dose-response assay and Time-of-Addition (ToA) assay have been developed, optimized, validated and utilized to identify novel antivirals against Bluetongue virus (BTV), as well as to determine the possible Mechanism-of-Action (MoA) for newly identified antivirals.
Related Videos
Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay Systems
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Qualitative and Quantitative Assays for Detection and Characterization of Protein Antimicrobials
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro
Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples
Identification of Coding and Non-coding RNA Classes Expressed in Swine Whole Blood
Copyright © 2024 MyJoVE Corporation. 판권 소유